This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (Formula One). ##STR00001##

Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.

Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.

Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds.

Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds.

Described herein are compounds that are EP.sub.4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP.sub.4 receptors.

Described herein are compounds that are EP.sub.4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP.sub.4 receptors.

Provided are: a nucleating agent for a polyolefin resin having an excellent crystal-forming effect; a nucleating agent composition for a polyolefin resin containing the nucleating agent; a polyolefin resin masterbatch; a polyolefin resin composition; a molded article of the composition; a film of the composition; a method of producing a porous film; and a package. The nucleating agent contains a compound represented by Formula (1) below wherein M represents a monovalent to trivalent metal atom having a specific gravity of 4.0 or less, or the like; a represents 1 or 2; b represents 1 or 3; x represents an integer of 1 to 3; ax=2b is satisfied; and Z represents a group represented by Formula (2) or (3) below wherein * represents a position at which each group is linked with Z of Formula (1); Y represents a direct bond or an alkylene group having 1 to 4 carbon atoms; and R.sub.1 to R.sub.10 each independently represent a hydrogen atom, a hydroxy group, a halogen atom, an alkyl group having 1 to 10 carbon atoms, or the like. ##STR00001##

Provided are: a nucleating agent for a polyolefin resin having an excellent crystal-forming effect; a nucleating agent composition for a polyolefin resin containing the nucleating agent; a polyolefin resin masterbatch; a polyolefin resin composition; a molded article of the composition; a film of the composition; a method of producing a porous film; and a package. The nucleating agent contains a compound represented by Formula (1) below wherein M represents a monovalent to trivalent metal atom having a specific gravity of 4.0 or less, or the like; a represents 1 or 2; b represents 1 or 3; x represents an integer of 1 to 3; ax=2b is satisfied; and Z represents a group represented by Formula (2) or (3) below wherein * represents a position at which each group is linked with Z of Formula (1); Y represents a direct bond or an alkylene group having 1 to 4 carbon atoms; and R.sub.1 to R.sub.10 each independently represent a hydrogen atom, a hydroxy group, a halogen atom, an alkyl group having 1 to 10 carbon atoms, or the like. ##STR00001##

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R.sup.1, and R.sup.2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

##STR00001##